NCT06481475: An ongoing trial by Chongqing Claruvis Pharmaceutical Co., Ltd.
This trial is ongoing. It must report results 2 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06481475 |
|---|---|
| Title | A Randomized Double-blind Vehicle-controlled Parallel-dose Phase II Study Evaluating the Safety and Efficacy of a Recombinant Botulinum Neurotoxin Type A Injection (YY003) for the Treatment of Moderate to Severe Glabellar Lines in Adults |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 9, 2025 |
| Completion date | Oct. 22, 2025 |
| Required reporting date | Oct. 22, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 3, 2026 |
| Days late | None |